In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4394-4397

  Stubbings, Will ^a   Leow, Pamela ^b   Yong, Goh Chee ^b   Goh, Falicia ^b   Körber Irrgang, Barbara ^c   Kresken, Michael ^c   Endermann, Rainer ^d   Labischinski, Harald ^a  

^a MerLion Pharmaceuticals GmbH   (Germany)

^b MerLion Pharmaceuticals Pte Ltd   (Singapore)

^c Antiinfectives Intelligence GmbH   (Germany)

^d BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; FINAFLOXACIN; LEVOFLOXACIN;

ACIDITY; ANTIBACTERIAL ACTIVITY; ARTICLE; ENTEROBACTER; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NEISSERIA GONORRHOEAE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEUS MIRABILIS; PROVIDENCIA; PSEUDOMONAS AERUGINOSA; SALMONELLA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; ESCHERICHIA COLI; FLUOROQUINOLONES; HYDROGEN-ION CONCENTRATION; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 80051819333     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00833-10     Document Type: Article

References (16)

1. Byerly, T C 1953. Handbook of biological data. Science 118:3.
2. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M07-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. Document M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Dalhoff, A., S. Schubert, and U. Ullmann. 2005. Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolones, macrolides, and a ketolide. Infection 33(Suppl. 2):36-43.
5. Dalhoff, A., W. Stubbings, and S. Schubert. 2011. Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine. Antimicrob. Agents Chemother. 55:1814-1818.
6. Emrich, N C, A. Heisig, W. Stubbings, H. Labischinski, and P. Heisig. 2010. Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance. J. Antimicrob. Chemother. 65:2530-2533.
7. Endermann, R., C. Ladel, W. Stubbings, and H. Labischinski. 2008. Pharmacokinetics (PK) and in vivo efficacy of oral finafloxacin (FIN) and comparators in rodent models of systemic infection, poster F1-2044. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
8. Endermann, R., C. Ladel, W. Stubbings, and H. Labischinski. 2008. In vivo efficacy of finafloxacin in difficult to treat animal models of infection, poster F1-2045. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
9. Higgins, P G, W. Stubbings, H. Wisplinghoff, and H. Seifert. 2010. Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacin-sensitive and -resistant Acinetobacter baumannii isolates. Antimicrob. Agents Chemother. 54:1613-1615.
10. Jacquot, J., O. Tabary, and A. Clement. 2008. Hyperinflammation in the airways of cystic fibrosis patients: What's new? Expert Rev. Mol. Diagn. 8:359-363. (Pubitemid 351962082)
11. Kresken, M., B. Körber-Irrgang, H. Labischinski, and W. Stubbings. 2008. Effect of pH on the in vitro activity of finafloxacin against gram-negative and gram-positive bacteria, poster F1-2037. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
12. Owens Jr., R C, and P G Ambrose. 2005. Antimicrobial safety: Focus on fluoroquinolones. Clin. Infect. Dis. 41:S144-S157 (Pubitemid 40962485)
13. Patel, H., et al. 2008. A phase I study to determine safety, tolerability and pharmacokinetics (PK) of finafloxacin (FIN) in healthy subjects, poster F1-2048. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
14. Schmuck, G., G. Wasinska-Kempka, A. Vente, and H. Labischinski. 2008. In vitro toxicological profiling of finafloxacin, poster F1-2047. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
15. Smith, S M, R H K Eng, and C E Cherubin. 1988. Conditions affecting the results of susceptibility testing for the quinolone compounds. Chemotherapy 34:308-314.
16. Yoon, S S, et al. 2006. Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J. Clin. Invest. 116:436-446.